Freshleaf Analytics H1 2021 report

FreshLeaf Analytics H1 2021

The FreshLeaf H1 2021 product, pricing and patient analysis was based on data collected in the period January and February 2021. The team collected product and pricing data in January and February 2021 from 45 suppliers who have been granted authority from the Office of Drug Control to supply medicinal cannabis into the Australian market.

Key highlights include:

  • Medicinal cannabis revenue expected to exceed expectations
    in 2021, hitting the $200m mark.
  • Patient numbers have grown by a factor of 15x over the
    past two years.
  • Significant increase in Authorised Prescribers after a long
    period of stagnation is a key driver of market growth.
  • Intense product competition continues as new products
    flood the market keeping downward pressure on price.
  • Average daily dose and average monthly spend stabilise.